Disulfiram reverses fluconazole-resistance mediated by Cdr1 in Candida albicans and interferes with biofilm formation Authors: Ahmed Rezk, Heba S Said, Sherin M Elfeky, Mohammed El-Mowafy, Ramadan Hassan Published: 2026 ABSTRACT AbstractAbstractThe incidence of Candida albicans infections has risen markedly, particularly among immunocompromised individuals and cancer patients undergoing chemotherapy. Fluconazole is commonly used as a first-line treatment for C. albicans infections; however, increasing clinical resistance poses a significant therapeutic challenge. As a result, developing new strategies to enhance the management of C. albicans infections has become critical. This study aims to assess the prevalence of azole’s resistance among clinical C. albicans isolates in Egypt and to evaluate disulfiram/fluconazole combination against fluconazole resistant isolates. A total of 64 C. albicans clinical isolates were tested for fluconazole susceptibility using disc diffusion method and broth microdilution method (alone and in combination with disulfiram). The combination of fluconazole and disulfiram was further assessed using checkerboard method. The expression levels of resistance determinants were analyzed using RT-PCR. Molecular docking was used for further analysis. Sixteen isolates (25%) were resistant to fluconazole. Combination with subinhibitory concentration of disulfiram reduced the minimum inhibitory concentration (MIC) of fluconazole in resistant isolates (2–128 fold). Checkerboard assay revealed that fluconazole/disulfiram combination was mostly synergistic. In fluconazole-resistant isolates, Cdr1 was overexpressed, whereas disulfiram (at subinhibitory concentration) has triggered its downregulation. Docking studies showed that disulfiram may compete with ATP for binding and may disrupt fluconazole's interaction with Cdr1. Additionally, disulfiram exhibited a potent anti-biofilm activity against the tested C. albicans isolates. Fluconazole/disulfiram combination appears to be a promising approach for overcoming fluconazole resistance in C. albicans. Further studies are needed to validate this finding and explore its clinical potential.Key points• Fluconazole/disulfiram combination is a promising approach to overcome fluconazole resistance in C. albicans• Disulfiram triggered downregulation of Cdr1 expression in fluconazole-resistant C. albicans.• Disulfiram competes with ATP for Cdr1 binding, disrupting fluconazole-Cdr1 interaction.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s00253-026-13977-w.Keywords: Candida albicans, Fluconazole-resistance, Fluconazole, Disulfiram, Efflux pump, Cdr1 Introduction Candida albicans (C. albicans) is a yeast that naturally exists as a part of the human microbiota, particularly in the mouth and vaginal tract (Makled et al. 2024). While it normally coexists in healthy individuals, it can become pathogenic under certain conditions, such as a weakened immune system, antibiotic use, or hormonal changes. When this balance is disrupted, C. albicans can overgrow and cause infections known as candidiasis (Ho et al. 2021). These infections range from superficial, such as oral thrush and vaginal yeast infections, to more serious systemic infections, especially in immunocompromised individuals (Ho et al. 2021; Makled et al. 2024). As an opportunistic pathogen, C. albicans is of significant clinical importance due to its adaptability, resistance mechanisms, and ability to form biofilms, which contribute to persistent infections (Makled et al. 2024). Fluconazole, a first-generation triazole, is known for its strong lipophilicity and low toxicity (Carmo et al. 2023). It is commonly used as a first-line treatment for both the prevention and management of C. albicans infections (Pappas et al. 2016). However, in recent years, the development of resistance mechanisms has significantly reduced the effectiveness of antifungal therapies, leading to decreased sensitivity of C. albicans to fluconazole (Carmo et al. 2023). This growing resistance hinders the drug’s ability to penetrate fungal cells and reduces available antifungal targets (Czajka et al. 2023). Overexpression of the ERG11 gene increases the amount of the target enzyme, while mutations of the gene impair fluconazole’s binding to its target enzyme. Furthermore, increased expression of efflux pump genes especially Cdr1 reduces the intracellular concentration of the drug in C. albicans (Rogers and Barker 2003; Sharma et al. 2024). Cdr1 is a plasma membrane protein composed of two homologous halves, each containing a cytoplasmic hydrophilic nucleotide-binding domain (NBD) and a highly hydrophobic TMD with reverse topology (Rawal et al. 2016). The TMD forms the substrate-binding site, while the NBD contains the ATP-binding site where hydrolysis occurs. Structurally, the NBDs are highly conserved across different transporters, whereas the TMDs are less conserved (Locher 2016). In its resting state, Cdr1 adopts an inward-facing conformation that allows substrates such as azoles to enter from the cytoplasm and bind to the central hydrophobic cavity within the transmembrane domains (TMDs). Efflux of the substrate is driven by ATP hydrolysis: ATP molecules bind to the nucleotide-binding domains (NBDs), inducing their dimerization. This conformational change shifts the TMDs to an outward-facing orientation, enabling the substrate to be expelled. Following ATP hydrolysis, Cdr1 resets to the inward-facing conformation, ready to transport additional substrates. Inhibition of Cdr1 prevents the efflux pump from transporting antifungal drugs such as fluconazole out of the cell, thereby enabling the drugs to accumulate in the cytoplasm and evading this resistance mechanism (Peng et al. 2024; Prasad and Rawal 2014). The emerged fluconazole-resistant strains can lead to repeated infections and/or failure of treatment presenting a challenge in hospital settings. As a result, recent studies have focused on discovering new drugs and/or therapeutic approaches that can enhance C. albicans' sensitivity to fluconazole (Sharma et al. 2024). Disulfiram (Tetraethylthiuram disulfide) is an approved medication used in aversion therapy for alcohol use disorder (Lanz et al. 2023). It supports sobriety by triggering unpleasant reactions, including headaches, nausea, and vomiting, when alcohol is consumed. Disulfiram’s therapeutic effect is primarily due to its ability to inhibit aldehyde dehydrogenase in the liver, which disrupts the breakdown of acetaldehyde (Lanz et al. 2023). Beyond its use in alcohol treatment, disulfiram has been investigated as a dopamine-β-hydroxylase inhibitor for managing cocaine addiction (Schottenfeld et al. 2014). Its potential for drug repurposing has also been examined in different fields including oncology and infectious disease, particularly as antibacterial agent or antibiotic enhancer (Custodio et al. 2022). This study examines a new approach for improving the treatment of C. albicans infections by using a combination of disulfiram and fluconazole in vitro to counteract fluconazole resistance in C. albicans isolates obtained from different clinical sources. The research also investigates the molecular mechanisms underlying this resistance reversal. Methods Isolation and identification of C. albicans isolates C. albicans isolates were collected from different clinical sources from different hospitals in Dakhlya governorate, Egypt. The study was approved by Research Ethics Committee of Faculty of Pharmacy, Mansoura University, Egypt (Code number: 2022–55). The isolates are available upon reasonable request from Ahmed Rezk (ahmedrezkragab@mans.edu.eg). Clinical isolates were identified as C. albicans based on conventional mycological examination including growth on Yeast Peptone Dextrose (YPD) agar and identification of their characteristic colonies, growth on CHROMagar Candida medium (Merck, Germany), and performing germ tube test, in which fungal isolates were enhanced to form germ tubes at 37℃ in Bovine serum albumin (BSA) (Thermofisher scientific, USA) within 2–3 h (Marinho et al. 2010; Pincus et al. 2007). Standard strain SC5314 was included in the study (Nishimoto et al. 2019). All isolates were stored in yeast peptone dextrose (YPD, 1% yeast extract, 2% peptone, and 2% dextrose) broth mixed with glycerol at −80℃. Prior to any experiment, isolates were sub-cultured in YPD broth medium and incubated on shaker incubator (IKA, Germany) at 160 rpm/min at 35℃ for 18–24 h. Then, isolates were streaked on YPD agar medium, incubated at 35℃ for 18–24 h and pure colonies of C. albicans isolates were picked for subsequent analysis. Antifungal susceptibility testing of C. albicans isolates C. albicans isolates were tested for their susceptibility to fluconazole using disk diffusion method according to Clinical and Laboratory Standard Institute (CLSI), M44-A3 guidelines (CLSI_M44-A3 2018). In brief, three to five colonies of pure C. albicans isolates were inoculated in sterile saline and the turbidity of the resulting suspension were adjusted to 0.5 McFarland standard using spectrophotometer at OD530nm. This procedure yielded a stock suspension of 1–5 × 106 cells/ml. A sterile swab was dipped into the adjusted suspension and streaked over Yeast Peptone Dextrose (YPD) agar plate. Fluconazole disk (FLU 25 µg, Liofilchem, Italy) was added to the inoculated plate using sterile forceps and the plate was incubated at 37℃ for 24 h in inverted position. The diameter of the inhibition zone around fluconazole disk was measured, and the result was interpreted according to the guidelines of Clinical and Laboratory Standard Institute (CLSI M44-A3, and CLSI M27M44S) (CLSI_M27M44S; CLSI_M44-A3 2018). Determination of MIC of fluconazole against C. albicans isolates The minimum inhibitory concentration (MIC) of C. albicans isolates against fluconazole (Sigma-Aldrich, Saint Louis, MO, USA) was determined using microbroth dilution method according to Clinical and Laboratory Standards Institutes (CLSI) guideline protocol M27-A4 (CLSI_M27-A4 2017) with some modifications. Briefly, two-fold serial dilutions of fluconazole were prepared in Yeast Peptone Dextrose (YPD) broth and applied in a 96-well microtiter plates. Three to five colonies of pure C. albicans isolates were inoculated in sterile saline and the turbidity of the resulting suspension were adjusted to 0.5 McFarland standard using spectrophotometer at OD530nm. This procedure yielded a stock suspension of 1–5 × 106 cells/ml, approximately. A working suspension is made by 1:100 dilution of the stock solution. The diluted cultures were applied to fluconazole dilutions (final cell density of 0.5–2.5 × 103 cells/ml, approximately). Positive and negative control wells were included of fungal cultures without fluconazole and medium only, respectively. The plates were then incubated at 37℃ for 24 h. Fungal growth was measured using microplate reader. Screening the effect of disulfiram on fluconazole resistance in C. albicans isolates MIC of disulfiram (Sigma-Aldrich, Saint Louis, MO, USA) against randomly selected fluconazole-resistant C. albicans isolates was determined using microbroth dilution method as described previously (CLSI_M27-A4 2017). Thereafter, MIC of fluconazole alone and in combination with sub-inhibitory concentration of disulfiram was determined using microbroth dilution method as described previously (CLSI_M27-A4 2017). Assessment of fluconazole combination with disulfiram using the checkerboard method The combination of fluconazole and disulfiram was further assessed using the checkerboard method in a 96-well microtiter plate against six representative fluconazole-resistant C. albicans isolates (Norozipor et al. 2024; Roana et al. 2021). In brief, two-fold serial dilutions of fluconazole and disulfiram (1/8 to 4 times the estimated MIC) were prepared in sterile tubes. Different combinations of fluconazole and disulfiram were combined in a 96-well microtiter plate. The wells were then inoculated with a diluted culture (final cell density 0.5–2.5 × 103 cells/ml) and incubated at 37 °C for 24 h. Negative control (medium only) and positive control (inoculated medium) were included. Fungal growth was measured spectrophotometrically at OD530nm, and MIC and fractional inhibitory concentration (FIC) were calculated. Combination of fluconazole and disulfiram were assessed by calculation of fractional inhibitory concentration index (FICI) according to the following equation: FICI = FICFlu + FICDis, where: FICFlu = MICFlu(combination)/MICFlu(alone), FICDis = MICDis(combination)/MICDis(alone). The interpretation of FICI was as follows: synergism (FICI ≤ 0.5), partial synergy (0.5 < FICI < 1), additive (FICI = 1), indifferent (1 < FICI ≤ 4), or antagonism (FICI > 4) (Gonzales et al. 2015). Analysis of the relative expression of resistance determinants using RT-PCR technique Two randomly selected fluconazole-resistant C. albicans isolates (Ca15 and Ca39) were used for analysis of relative expression of Cdr1 gene using RT-PCR technique under different conditions. The selected C. albicans isolates were incubated with fluconazole or disulfiram or their combination for 16 h at 37℃. The cells were harvested from the YPD broth by centrifugation (Tong et al. 2021). Total RNA was extracted using Trizol reagent (Grisp) followed by DNAse treatment. RNA concentration was determined using Nanodrop (BioDrop DUO + Micro-volume Spectrophotometer). The ratio of 260/280 and run on agarose gel were used to evaluate the purity and quality of the extracted RNA. Subsequently, RNA was converted to cDNA using cDNA synthesis kit (Thermo Scientific Revert Aid First Strand cDNA Synthesis Kit #K1622) according to the manufacturer's instructions. Gene-specific primers for Cdr1 were used for the detection of Cdr1 gene (Table 1). The 18S rRNA gene was used as an internal reference gene in all experiments. For RT-PCR, HERAPLUS SYBR® Green qPCR Kit (Willowfort, England) and Rotor Gene Q Real-Time PCR System (Qiagen, Netherlands) were used. The cycling conditions were as follows: initial denaturation at 95 °C for 2 min, followed by 40 cycles of denaturation at 95 °C for 10 s, and annealing at 55 °C for 30 s. No template control reaction was included in every run. Melting curve analysis was performed to ensure amplification of specific PCR products. The relative fold change in gene expression was calculated using the 2−ΔΔCT method (Yang et al. 2025). Table 1List of primers used in this studyGene namePrimer namePrimer sequence (5'—3')Amplicon Size (bp)ReferenceCdr1Cdr1_FwGATTCTCAAACTGCCTGGTC136 Tong et al. 2021Cdr1_RvCCAAAATAAGCCGTTCTTCCAC18S_rRNA18S_rRNA_FwTCTTTCTTGATTTTGTGGGTGG14918S_rRNA_RvTCGATAGTCCCTCTAAGAAGTGbp base pair, Fw forward primer, Rv reverse primer List of primers used in this study bp base pair, Fw forward primer, Rv reverse primer Molecular docking simulation studies Docking studies were conducted following the methodology outlined in the literature (Meng et al. 2011). The crystallographic structure of Cdr1 of C. albicans with fluconazole at the hydrophobic cavity of the TMD (PDB ID: 9IUL) (Peng et al. 2024) was obtained from the Protein Data Bank (PDB) and prepared for molecular docking by adding hydrogens and minimizing energy using MOE 2024.06. The structure with the lowest energy was selected as the docking receptor. MOE’s site finder method was used to identify the hydrophobic cavity of Cdr1. To validate the docking process, the co-crystallized ligand fluconazole was re-docked into hydrophobic cavity of Cdr1. The root mean square deviation (RMSD) between the re-docked ligand and the co-crystallized position was found to be less than 2 Å. Site finder algorithm of MOE was also used to identify ATP binding site of Cdr1, ATP was docked into the ATP binding site. ATP was re-docked into ATP binding site of Cdr1. The root mean square deviation (RMSD) between the re-docked ATP and the dummies was found to be less than 2 Å. Two-dimensional structure of disulfiram was created using Chem Bio Office, then built from fragment libraries in MOE 2024.06, followed by energy minimization using the MMFF94x force field. Docking was conducted using selected parameters (rescoring functions 1 and 2: London) to investigate and analyze the interactions between the ligands and substrate binding site and the ATP binding site of Cdr1. Biofilm inhibition and eradication capacity of disulfiram The capability of disulfiram in inhibition of biofilm formation and eradication of mature biofilm by C. albicans clinical isolates was evaluated using a tissue culture plate method as described previously with some modifications (Mendes et al. 2024; Wu et al. 2024). Biofilm inhibition assay For untreated control, diluted fungal suspension (1 X 106 cells/ml) in YPD broth was applied in 96-microtiter polystyrene plate (Thermofisher scientific, USA). For treated wells, fungal culture was subjected to disulfiram at sub-MIC concentrations (1/2, 1/4, 1/8, and 1/16 MIC). The plates were incubated at 37℃ for 24 h without shaking. The non-adherent cells were aspirated then rinsed with sterile phosphate buffered saline three times. Then 200 μL of 99% methanol per well was added and left for 15 min for biofilm fixation. The wells were then decanted and left to dry. The plates were then stained using crystal violet (1% w/v), with additional stain flushed under running water. After drying, 200μL of glacial acetic acid (33%) were transferred to each well to resolubilize the bound crystal violet, which was measured spectrophotometrically at OD570nm using ELISA plate reader (BioTek Instruments Inc., Winooski, VT). Negative control wells of YPD broth only were included. The assay was performed in triplicate. To calculate the inhibition percentage, the following equation was used: Biofilm eradication assay Eradication of mature biofilm was evaluated using the same protocol for biofilm inhibition assay, allowing the formation of mature fungal biofilm after 24 h incubation at 37 °C. Under aseptic conditions, the wells were decanted, rinsed three times, and left to dry. Disulfiram was distributed into wells at sub-MIC concentration (1/2, 1/4, 1/8, and 1/16 MIC). The plates were re-incubated at 37 °C overnight. Biofilm was stained, and the percentage eradication of mature biofilm was estimated as previously described. Statistical analysis All data were evaluated using SPSS software—version 25 (Chicago, IL, USA). Data of three independent experiments are presented as mean ± standard deviation (SD). Statistical analysis was performed using Student’s t-test. P < 0.05 was considered statistically significant. Results Isolation and identification of C. albicans clinical isolates Sixty-four C. albicans isolates were collected from different clinical sources including: urine (22 isolates), vaginal swabs (19 isolates), blood (12 isolates), and other sources (11 isolates). The clinical isolates were collected during the period from May to July 2022 from different hospitals in Dakhlya governorate, Egypt. Isolates were identified as C. albicans based on standard microbiological laboratory protocols including growing on Yeast Peptone Dextrose (YPD) agar, examination on CHROMagar Candida medium (Merck, Germany), and germ tube test. Fluconazole susceptibility testing Susceptibility of C. albicans clinical isolates against fluconazole was determined using disc diffusion method. Sixteen isolates (25%) were resistant to fluconazole (Table S1). MIC of fluconazole-resistant isolates was determined using microbroth dilution method. MIC values ranged from 64 to 2048 µg/ml (Table S1). Six fluconazole resistant isolates (Ca13, Ca14, Ca15, Ca32, Ca33, and Ca39) with different fluconazole MIC values were randomly selected for the further studies. Screening of the effect of disulfiram on C. albicans resistance to fluconazole Variable MIC values (10–20 µg/ml) of disulfiram against the selected C. albicans clinical isolates were determined using microbroth dilution method (Table 2). The effect of sub-inhibitory concentration of disulfiram on fluconazole resistance was estimated (Table 2). Disulfiram considerably reduced the MIC of fluconazole against most of the selected isolates. It decreased MIC of fluconazole by 2- to 128-fold and therefore could be considered a potential inhibitor of fluconazole resistance. Table 2Effect of disulfiram on resistance to fluconazole in C. albicans clinical isolatesIsolate NoMIC of Dis (µg/ml)Conc used of Dis (µg/ml)MIC of Flu (µg/ml)MIC of Flu in combination with Dis (µg/ml)Fold ChangeCa13105128642-foldCa142010512648-foldCa15105512648-foldCa322010256328-foldCa33105128324-foldCa3910510248128-foldDis disulfiram, Flu fluconazole Effect of disulfiram on resistance to fluconazole in C. albicans clinical isolates Dis disulfiram, Flu fluconazole Assessment of fluconazole combination with disulfiram using the checkerboard method The combination of fluconazole with disulfiram was further assessed using the checkerboard method (Table 3 and Fig. 1). The combination of fluconazole and disulfiram was mostly synergistic. Three isolates showed synergistic effect (FICI ≤ 0.5) and two isolates showed partial synergy (0.5 < FICI < 1). Only one isolate showed additive effect (FICI = 1) (Table 3 and Fig. 1). Table 3Effect of disulfiram on resistance to fluconazole in C. albicans clinical isolates using checkerboard methodIsolate NoFluconazoleDisulfiramFICI(Flu/Dis)Combined effectMIC (alone)MIC (combination)FIC(Flu)MIC (alone)MIC (combination)FIC(Dis)Ca13128640.51050.51AdditiveCa145121280.252050.250.5SynergyCa15512640.1251050.50.625Partial SynergyCa32256640.252050.250.5SynergyCa33128640.5101.250.1250.625Partial SynergyCa39102480.00781050.50.5078SynergyFICI fractional inhibitory concentration index, FIC fractional inhibitory concentration, Dis disulfiram, Flu fluconazole Effect of disulfiram on resistance to fluconazole in C. albicans clinical isolates using checkerboard method FICI fractional inhibitory concentration index, FIC fractional inhibitory concentration, Dis disulfiram, Flu fluconazole Isobolograms of disulfiram and fluconazole combination in C. albicans clinical isolates using checkerboard method Expression levels of fluconazole resistance determinants in C. albicans clinical isolates The effect of disulfiram on the expression of efflux pump gene Cdr1 was assessed using RT-PCR technique, and the relative expression level was calculated using 2−△△Ct method. The expression level of Cdr1 gene was up-regulated under fluconazole at sub-inhibitory concentration compared to that of control experiment (non-treated control) (Table 4). The melting curves and peaks of Cdr1 and 18S rRNA gene amplicons showed no signs of non-specific amplification or primer-dimer formation during the reactions. Additionally, gel electrophoresis revealed a single band of the expected size for each PCR product, further confirming the specificity of the amplification. Table 4Estimation of the relative expression level of Cdr1 gene using RT-PCR method in fluconazole-resistant C. albicans clinical isolatesIsolate No2−△△CtIsolate(Nc)Isolate(Flu)Isolate(Dis)Isolate(Flu/Dis)Ca15165.8 ± 2.17***0.7 ± 0.08*11.16 ± 0.69**Ca391153.28 ± 3.1***0.17 ± 0.01***39.4 ± 1.25***Nc non-treated control, Flu fluconazole, Dis disulfiramData presented as Mean ± SD, Student’s t-test was used to compare expression level relative to Isolate (Nc) and P < 0.05 was considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001) Estimation of the relative expression level of Cdr1 gene using RT-PCR method in fluconazole-resistant C. albicans clinical isolates Nc non-treated control, Flu fluconazole, Dis disulfiram Data presented as Mean ± SD, Student’s t-test was used to compare expression level relative to Isolate (Nc) and P < 0.05 was considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001) Disulfiram (at sub-inhibitory concentrations) caused down-regulation of Cdr1 expression compared to non-treated control. Moreover, when combined with fluconazole, disulfiram also decreased the expression of Cdr1 gene compared to that of fluconazole alone (Table 4). Molecular docking simulation studies Fluconazole binds within the hydrophobic cavity of Cdr1 transmembrane domain (TMD, PDB: 9IUL) (Peng et al. 2024; Prasad and Rawal 2014), primarily via hydrophobic interactions with several residues, including Phe552, Leu555, Phe556, Phe559, Leu668, Val668, Ile1237, and Thr1355. Additionally, fluconazole forms a hydrogen bond with Asn1240 through its 1,2,4-triazol-1-yl moiety (Fig. 2, Panel a). Similarly, at the substrate-binding site, disulfiram interacts in a mode comparable to fluconazole, forming a hydrogen bond with Asn1240 and hydrophobic contacts with residues Phe559, Leu664, Leu555, Ile1237, Phe552, and Met657. The calculated binding affinity of disulfiram (−6.46 kcal/mol) is higher than that of fluconazole (−6.07 kcal/mol), suggesting stronger binding at the same site (Fig. 2, Panel b). Molecular docking of Fluconazole and Disulfiram at the hydrophobic cavity in the TMD, and the ATP binding site in the NBD of Cdr1 (PDB: 9IUL). Panel a Fluconazole (Purple) and Panel b Disulfiram (Green) aligned at fluconazole (purple) at the hydrophobic cavity in the TMD of Cdr1. Panel c ATP (purple) and Panel d Disulfiram (Green) aligned at ATP (purple) at the ATP binding site in the NBD of Cdr1 The ATP-binding site of Cdr1 contains the conserved Walker A and Walker B motifs (Rawal et al. 2016). Within the Walker A motif, Cys193 is critical for ATP hydrolysis, as substitution of this residue was reported to drastically reduce ATPase activity and increase drug susceptibility. The ATP-binding site also involves residues Thr195, Gly192, Lys198, Glu238, and Asn328, with Thr195 being essential for interaction with ATP (Fig. 2, Panel c). Disulfiram showed similar mode of interaction to that of ATP at the ATP site, forming hydrogen bonds with Thr195, Cys193, Gly190, Ser194, and Gly192, with lower binding affinity (−5.43 kcal/mol) compared to that of ATP (−6.95 kcal/mol) (Fig. 2, Panel d). Biofilm inhibition and eradication capacity of disulfiram The effect of disulfiram, at sub-inhibitory concentrations tested (1/2, 1/4, 1/8, and 1/16 MIC), on the inhibition of biofilm formation and eradication of mature biofilm of C. albicans clinical isolates was evaluated using tissue culture plate method. The results indicated a dose-dependent reduction in biofilm formation and eradication (Table 5). Disulfiram exhibited a potent anti-biofilm activity against the tested C. albicans isolates. Even at 1/16 MIC of disulfiram, it significantly reduced biofilm formation and eradication of mature biofilm with recorded inhibition of 14 to 37% approximately (Table 5). Table 5Inhibition of biofilm formation and eradication of mature biofilm by disulfiram against C. albicans clinical isolatesEffect of DisulfiramCa14Ca15Ca39% Reduction of biofilm formation1/2 MIC74.66 ± 3.02**72.76 ± 2.47***73.11 ± 3.84***1/4 MIC45.24 ± 2.27*57.63 ± 3.95**60.32 ± 2.09**1/8 MIC21.16 ± 1.2139.71 ± 2.08*36.61 ± 1.31**1/16 MIC14.29 ± 0.9530.99 ± 1.34*26.19 ± 0.91% Eradication of mature biofilm1/2 MIC67.85 ± 3.52***60.31 ± 2.46***64 ± 0.78***1/4 MIC48.44 ± 2.74**54.76 ± 2.84***59.85 ± 0.44***1/8 MIC33.41 ± 1.83***46.12 ± 1.17**46.12 ± 0.37***1/16 MIC15.22 ± 0.8932.55 ± 0.74*36.98 ± 0.32***Data presented as Mean ± SD, Student’s t-test was used and P < 0.05 was considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001) Inhibition of biofilm formation and eradication of mature biofilm by disulfiram against C. albicans clinical isolates Data presented as Mean ± SD, Student’s t-test was used and P < 0.05 was considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001) Discussion The emergence of resistance to antifungal agents among C. albicans isolates poses a significant public health threat, especially for azoles, which continue to be the primary treatment for many forms of candidiasis. Recent studies in Egypt have reported elevated levels of fluconazole resistance in C. albicans isolates from bloodstream infections (58.3%), whereas fluconazole resistance among vulvovaginal isolates was considerably lower (11.3%) (Dawoud et al. 2024; Gerges et al. 2023). The elevated resistance rate may be linked to long-term empirical treatment with fluconazole, along with the infrequent practice of routine antifungal susceptibility testing (El-Ganiny et al. 2021; Gerges et al. 2023). Several underlying mechanisms have contributed to the exaggeration of the resistance to fluconazole in clinical isolates of C. albicans (Gerges et al. 2023). Overexpression of efflux pumps specifically ATP-binding cassette (ABC) transporters (Cdr1 and Cdr2), and major facilitator (MFS) transporter Mdr1 actively reduce the intracellular drug concentration below therapeutic thresholds. ERG11 gene point mutations alter the target enzyme lanosterol demethylase, reducing its binding affinity for fluconazole (Shukla et al. 2004). These findings highlight the urgent need for improved antifungal stewardship and routine susceptibility surveillance in Egypt to prevent further escalation of resistance and to guide the selection of effective and suitable antifungal agents. fluconazole is one of the most frequently used and effective antifungal agents against C. albicans infections due to its wide spectrum and its favorable safety and pharmacokinetic profiles (Sobel 2023). The elevated resistance rates of C. albicans clinical isolates toward fluconazole directs research for the development of alternative strategies (Sharma et al. 2024). Combination therapy is a promising therapeutic approach to combat the developed resistance. This approach can lead to lowering effective drug concentrations and potential toxic doses, broadening the antifungal activity spectrum, and most importantly, reverting resistance (Sharma et al. 2024). The natural compound batzelladine D, isolated from a marine sponge, has been shown to reverse fluconazole resistance by competitively inhibiting Cdr1p-mediated efflux and disrupting biofilm formation (Domingos et al. 2024). Berberine is another natural compound that is capable of reversing fluconazole (FLC) resistance in C. albicans (Zhu et al. 2014 and Wu et al. 2024). The primary basis for its synergistic action with fluconazole is the downregulation of efflux pump genes whose overexpression is a major clinical resistance mechanism. Berberine can directly bind to the Cdr1 gene promoter, blocking the binding of the transcription factor and thereby inhibiting the upregulation of this efflux pump (Zhu et al. 2014). Concurrently, berberine disrupts fungal virulence and survival by impairing biofilm formation (Zhu et al. 2014). In parallel, the antipsychotic haloperidol, the proton pump inhibitor pantoprazole, and NSAIDs such as aspirin and ibuprofen act as chemosensitizers by inhibiting efflux pump function, significantly reducing fluconazole MIC in fluconazole-resistant isolates (Sharma et al. 2015 and El-Ganiny et al. 2022). An efficient and economical alternative is drug repurposing as adjuvants that enhance the efficacy of existing therapies (Hao et al. 2021). In addition to its role in treating alcohol dependence, disulfiram has been investigated for drug repurposing in areas such as oncology and infectious diseases. Studies have shown that methicillin-resistant Staphylococcus aureus (MRSA) can be inhibited by disulfiram at MIC as low as 1.33 μg/mL (Phillips et al. 1991). Another study reported an MIC₉₀ of 16 μg/mL against a panel of 30 S. aureus strains, including vancomycin-intermediate (VISA) and vancomycin-resistant (VRSA) variants (Long 2017). While most Gram-negative bacteria show resistance to disulfiram at concentrations up to 32 μg/mL, certain zoonotic pathogens remain susceptible (Custodio et al. 2022). Disulfiram has also shown inhibitory activity against Helicobacter pylori with an MIC of 1 μg/mL (Kobatake et al. 2021). Despite its limited efficacy against many clinically relevant Gram-negative species, disulfiram may still have therapeutic value as an inhibitor of metallo-β-lactamases and carbapenemases (Chen et al. 2020). Disulfiram was identified as a potent antifungal agent, exhibiting 50% growth inhibition of Candida species at concentrations as low as 1 mg/L. Another study reported an MIC₉₀ of 4 μg/mL against both C. albicans and C. glabrata (Khan et al. 2007). It also demonstrated antifungal activity against biofilm formation, with 50% minimum inhibitory concentrations (MIC₅₀) ranging from 32 to 128 mg/L across different Candida strains. Further analysis using scanning electron microscopy (SEM) and confocal laser scanning microscopy (CLSM) confirmed the disruption of biofilm architecture and significant alterations in biofilm morphology following exposure to disulfiram (Hao et al. 2021). In this study, the combination of disulfiram with fluconazole has been evaluated. Our results indicated that disulfiram and fluconazole combination is mainly synergistic against the tested fluconazole-resistant C. albicans isolates. Some studies indicated that disulfiram has a direct inhibitory action on efflux pumps by targeting the ATP-binding cassette (ABC) transporter Cdr1p, a major contributor to azole resistance in C. albicans (Shukla et al. 2004). Additionally, a non-toxic concentration of disulfiram (1 μM) was found to enhance the sensitivity of Saccharomyces cerevisiae cells expressing Cdr1p to various antifungal agents, including fluconazole, and miconazole (Shukla et al. 2004). Fluconazole resistance is associated with overexpression of efflux pump genes especially Cdr1. Disulfiram was able to downregulate the expression of efflux pump genes Cdr1 and revert fluconazole resistance. Cdr1 is a critical ATP-binding cassette (ABC) transporter that functions as an efflux pump in C. albicans (Prasad et al. 2015). It is a major contributor to azole resistance by actively exporting antifungal azoles from the cell, thereby reducing their intracellular concentrations and preventing toxic accumulation (Nakamura et al. 2001). Targeting Cdr1 efflux activity is a promising strategy to overcome azole resistance in C. albicans. Several inhibitors have been reported, including macrocyclics, cyclopeptides, peptidomimetics, phenol derivatives, terpene derivatives, and disulfiram (Holmes et al. 2016). These inhibitors act via diverse mechanisms, such as preventing ATP hydrolysis by forming disulfide linkages at conserved cysteine residues in the NBDs, competitively blocking ATP-binding, or interfering with substrate-binding at the TMDs. Notably, disulfiram has been shown to inhibit Cdr1 through all three mechanisms (Tran-Nguyen et al. 2017). Docking simulations of disulfiram at both the substrate and ATP-binding sites of Cdr1 revealed strong binding affinities at both binding sites, with binding modes resembling those of the native ligands, fluconazole and ATP, respectively. At the substrate-binding site, disulfiram may act as a competitive inhibitor of fluconazole, potentially allowing unbound fluconazole to remain in the cytoplasm longer and exert its antifungal activity against C. albicans. At the ATP-binding site, disulfiram forms hydrogen bonds with key residues Thr195 and Cys193, potentially disrupting ATP binding and hydrolysis, which are essential for efflux pump function. These results align with experimental observations showing that combining fluconazole with disulfiram reduces resistance compared to fluconazole alone. In summary, the study demonstrates elevated fluconazole resistance among C. albicans collected from different clinical sources in Egypt. The combination of disulfiram with fluconazole exhibited predominantly synergistic activity in vitro. Disulfiram downregulated the expression of the Cdr1 efflux pump and significantly inhibited biofilm formation. These findings identify disulfiram as a promising antifungal adjuvant. Further studies including site-directed mutagenesis, functional binding studies, and studying the efficacy of disulfiram on other resistance mechanisms such as ERG11 point mutation and the effect of other resistance genes (Cdr2, Mdr1) are needed. Additionally, given that these results are derived exclusively from in vitro experiments, further investigations are warranted to evaluate the in vivo efficacy and pharmacodynamic profile of disulfiram-fluconazole combination. Such studies are essential prior to drawing any clinical conclusions or advancing this therapeutic strategy toward clinical application. Supplementary Information Below is the link to the electronic supplementary material. (229 KB PDF) Acknowledgements We thank CCMML (Computational Chemistry and Molecular Modelling Lab), Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Mansoura University, where the molecular docking simulations were carried out. Author contributions The study was conceived and designed by RH, ME and HSS. Experimental work was performed by AR. AR, HSS and ME performed data preparation, interpretation, and analyses. AR and HSS wrote the manuscript. SME performed molecular docking analysis and wrote this part in the manuscript. RH, ME and HSS has revised the manuscript. Funding This study was self-funded. Data availability All data generated and analyzed during this study are included in this article and its supplementary information files. Declarations Ethics approval and consent to participate The study was approved by the Research Ethics Committee of the Faculty of Pharmacy, Mansoura University, Egypt (Code number: 2022–55). All procedures performed in the study involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments. Competing interest The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials (229 KB PDF) Data Availability Statement All data generated and analyzed during this study are included in this article and its supplementary information files.